Allocetra not checked

Enlivex Therapeutics Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Allocetra is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state.”In the company’s words, NCT07580716 on ClinicalTrials.gov
Tested for
Primary Knee Osteoarthritis
Main trialPhase 2
“This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).”In the company’s words, NCT07580716 on ClinicalTrials.gov

Other drugs for Primary Knee Osteoarthritis

All 48 drugs for Primary Knee Osteoarthritis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Feb 2027 Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
Phase 1/2Completed 15 Mar 2026 Study of Intra-articular Allocetra in Knee Osteoarthritis
Phase 1Terminated 20 Oct 2025 Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Allocetra

Following is part of Solo: you see every change to Allocetra the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in